This site is intended for healthcare professionals
News

Analysis of the impact of timing for Zejula maintenance treatment in newly diagnosed advanced ovarian cancer is presented at the 2022 International Gynecologic Cancer Society Meeting

Read time: 1 mins
Published:21st Sep 2022

Zai Lab Limited will present a poster featuring initiation timing analysis from the Phase III PRIME study of Zejuka (niraparib) as maintenance therapy at the upcoming 2022 International Gynecologic Cancer Society (ICGS) Annual Meeting

This post-hoc analysis of the PRIME Phase III study evaluated adults with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy, and they were randomized to receive niraparib maintenance treatment or placebo within 12 weeks after chemotherapy completion.

The results are as follows: i. For patients who received niraparib treatment less than 9 weeks after chemotherapy completion, the median progression-free survival (PFS) (95% CI) was measured at 29.4 months with niraparib versus 8.3 months with placebo (HR =0.31; 95% CI, 0.20–0.48). ii. For patients who received niraparib at 9 – 12 weeks after chemotherapy completion, the median PFS was 24.7 months with niraparib versus 10.8 months with placebo (HR=0.60; 95% CI, 0.41–0.89). iii. The initiation timing of niraparib maintenance treatment had no significant impact on its safety profile.This subgroup analysis provides evidence to support the initiation of niraparib maintenance treatment in patients with newly diagnosed advanced ovarian cancer within 12 weeks after chemotherapy completion.

Condition: Ovarian Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.